COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher’s Stone?
Theano Penlioglou, Stella Papachristou, Νικόλαος Παπάνας
Abstract
Corona virus infectious disease (COVID-19) is a new pandemic. In subjects with diabetes mellitus, infection may be more frequent and severe. We discuss the potential contribution of two traditional oral antidiabetic agents, metformin and pioglitazone, to the improvement of liver injury in COVID-19. Clearly, further experience is needed to shed light on these hypotheses.
Topics & Concepts
MedicineMetforminDiabetes mellitusCoronavirus disease 2019 (COVID-19)PioglitazonePandemicDiseaseInfectious disease (medical specialty)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineInternal medicineVirologyEndocrinologyType 2 diabetesOutbreakLiver Disease Diagnosis and TreatmentMetabolism, Diabetes, and CancerDiabetes Treatment and Management